
Opinion|Videos|March 20, 2025
Additional Data Needs for BTK Inhibitors in CSU
Panelists discuss how future research should focus on identifying biomarkers for patient selection, understanding long-term safety profiles, exploring combination therapy approaches, and determining optimal treatment duration with Bruton tyrosine kinase (BTK) inhibitors in chronic spontaneous urticaria (CSU).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What additional data, if any, is needed surrounding BTK inhibitors and CSU?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Screening and Diagnosis of Hypercortisolism in Type 2 Diabetes
2
Prevalence and Recognition of Hypercortisolism
3
Distinguishing CSU From Chronic Inducible Urticaria Subtypes
4
METRE-PL Data Shows Severe Metabolic Disease Burden in FPLD Despite Standard Therapy
5


























































































